Search
Immunic Inc
IMUXAdd to Watchlist
14.800USD
-0.010-0.07%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
20.16MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.07%
5 Days
-3.27%
1 Month
+2.56%
6 Months
+2438.59%
Year to Date
+2673.09%
1 Year
+1935.20%
Key Figures
14.960Open
15.500High
130.16KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
9.56%Turnover Ratio
14.810Prev. Close
14.500Low
1.41MTurnover
LossP/E Static
0.13P/B
0.00%Div Yield TTM
-99.20%ROA
15.40052wk High
1.14Volume Ratio
-100.51MNet Profit
1.36MShares
-14.5415EPS TTM
1.35Beta
-142.91%ROE
5.06252wk Low
6.75%Amplitude
--Gross Margin
20.16MMarket Cap
0.49Reward/Risk
5.36%Risk Rate
TradingKey Stock Score of Immunic Inc
Currency: USD Updated: 2026-07-02Key Insights
Immunic Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 82 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 43.22.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunic Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Immunic Inc Highlights
StrengthsRisks
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Undervalued
The company’s latest PE is -1.02, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 58.68M shares, increasing 27.51% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.85.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
43.222
Target Price
+191.84%
Upside Space
Immunic Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immunic Inc Info
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Ticker SymbolIMUX
CompanyImmunic Inc
CEOVitt (Daniel)
Websitehttps://imux.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Immunic Inc (IMUX)?
The current price of Immunic Inc (IMUX) is 14.80.
What is the symbol of Immunic Inc?
The ticker symbol of Immunic Inc is IMUX.
What is the 52-week high of Immunic Inc?
The 52-week high of Immunic Inc is 15.40.
What is the 52-week low of Immunic Inc?
The 52-week low of Immunic Inc is 5.06.
What is the market capitalization of Immunic Inc?
The market capitalization of Immunic Inc is 20.16M.
Is Immunic Inc (IMUX) currently rated as Buy, Hold, or Sell?
According to analysts, Immunic Inc (IMUX) has an overall rating of STRONG BUY, with a price target of 43.22.
What is the Earnings Per Share (EPS TTM) of Immunic Inc (IMUX)?
The Earnings Per Share (EPS TTM) of Immunic Inc (IMUX) is -6.24.